Check out the Moffitt Cancer Center experience with HMA+Ven in post-alloHCT AML relapse. Active in nearly half of patients with deep (MRD neg) and durable (>1.5 years on median) responses. authors.elsevier.com/a/1igx87fNb0Dz…

🌟Excited to announce the launch of PARAMUNE trial! Grateful to my supporters SWOG Cancer Research Network @NCICTEP_ClinRes. Together, we're pioneering frontiers in immunotherapy, offering hope to those in need. Let's make a difference! 💫UPMC Hillman Cancer Center philip a philip Dr. Cathy Eng @danduda9 Rajiv Agarwal MD

Among all USF fellows, two were selected for induction into the prestigious USF Robert A. Good Honor Society and these fellows are our very own: Zaker Schwabkey and Robin Park! We’re proud of you! Congratulations! 👏 Zaker Schwabkey, MD Robin Park, MD Moffitt Cancer Center USF Health

Will be missing out on #ASCO24😭 but super excited to see this published! Immensely grateful to Dr. Anwaar Saeed for the opportunity🙏 Check out 👉 Immunotherapy in Colorectal Cancer — Finding the Achilles’ Heel | NEJM Evidence evidence.nejm.org/doi/full/10.10… NEJM Evidence

Delighted & proud to share the outstanding work by Robin Park, MD showcasing cutting-edge advancements & foundational research in MSS #CRC immunotherapy! Check out our landmark review in prestigious NEJM Evidence NEJM Timely around ASCO UPMC Hillman Cancer Center ☕️🎻 evidence.nejm.org/doi/full/10.10…

🚨Now live #ASCO24 Evolving Approaches in HNSCC: State-of-the-Art Updates, chaired by Sana Karam, MD, PhD. 👋💡Sana Karam, MD, PhD provides an outstanding summary of the interplay between IO and RT. "Less is More." RT and IO isn't a one-size-fits-all strategy strategy; rather, we need thoughtful

Getting together with multiple generations of @NCICCR_MOS folks at ASCO is always a true joy! #ASCO24

Subsets of patients with colorectal cancer respond to immune checkpoint inhibitors (ICI). Drs. Robin Park, MD and Anwaar Saeed review the literature on strategies to improve the response of colorectal cancer to ICI. 1/2

🔥Excited to see our review out in Molecular Cancer Therapeutics!✨ We highlight the unmet needs & emerging therapies in HPV- R/M HNSCC🎯Grateful for the mentorship & guidance from Christine Chung✨Moffitt Hematology/Oncology Fellowship Moffitt Research aacrjournals.org/mct/article/do…

merck.com/news/mercks-ke… Robert Haddad Glenn J. Hanna, M.D. R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) Robert Ferris, MD, PhD Nabil Saba, MD Schmitt Lab Jonathan Schoenfeld Dr. Gavin P. Dunn Toni Choueiri, MD Kartik Sehgal

✨Thrilled to be attending AACR-KCA 2024 in Seoul to present the long-term FU & biomarker results from our cetux/nivo trial in R/M HNSCC ✨ Moffitt Research Moffitt Cancer Center 🔥Beyond grateful for the travel grant award AACR 🙏

Donghoon Shin, MD of @MetroWestMedCtr presents "Comprehensive Analysis of EGFR Exon 19 Deletion: Sequence, Epidemiology, and Molecular Architecture: Insights into NSCLC Therapy" #EGFR #MedEd #MedTwitter #MedX #EGFRSummit

Excited to share our publication on ctDNA in resected BTC JCO Precision Oncology! 🔗 https:ascopubs.org/doi/10.1200/PO… 👉ctDNA is prognostic for relapse (HR 20-26) 👉Outperforms CA19-9 for relapse correlation 👉Potentially Detects recurrence earlier (avg lead time 3.7 mo) #BTC #ctDNA #MRD

Happy #ASCO25 abstract results day!! Excited for this oral presentation of our work from ASCO IMG CoP including 15+ IMGs. Huge thanks to my team members & mentors Toni Choueiri, MD Fatemeh Ardeshir, MD Charles Jiang MD, MPH Arya Roy Nazli Dizman Ziad Bakouny, MD, MSc IMG Oncologists Moffitt Cancer Center

At #ASCO25: Robin Park, MD (Robin Park, MD) presents a phase II study exploring ACR-368 + low-dose gemcitabine in recurrent/metastatic head & neck cancer. #MoffittASCO25 #HNSCC #ImmunoOnc

During #ASCO25, Caitlin McMullen, MD (Dr. Caitlin McMullen) and Guilherme Rabinowits, MD joined us to discuss the emerging head and neck cancer research being presented at ASCO. #MoffittASCO25

From #ASCO25, Kedar Kirtane, MD (Kedar Kirtane, MD) shares early-phase data from DENALI-1, a study of A2B395—a logic-gated, allogeneic CAR T targeting EGFR in solid tumors with HLA LOH. This novel off-the-shelf approach aims to expand CAR T therapy safely into solid tumors.

Recently published: Plasma Cell-Free #HPV DNA and Oral Gargle HPV DNA in Patients with HPV-related #OropharyngealCancer Treated with #Radiotherapy, by Michelle Echevarria et al. doi.org/10.1158/2767-9… Robin Park, MD James Caudell Amelio Lab Moffitt Cancer Center #OpenAccess